TORONTO, Sept. 13,
2022 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a global
leader in medical cannabis throughout Europe and Latin
America, today announced that received the Best Latin
American Cannabis Company award at Benzinga's 2022 Cannabis Capital
Conference in Chicago.
"This award recognizes our efforts and achievements as a Latin
American Company that radiates throughout our international
footprint. Khiron Life Sciences is a first mover in developing a
global path for medical cannabis in the region, and we are pursuing
this approach worldwide. By providing access to medical cannabis
for doctors, pharmacists, insurers, and patients, we have created a
true end-to-end solution for the medical cannabis industry",
commented Alvaro Torres, CEO and
Director of Khiron Life Sciences.
Khiron has developed a proven international access business
model with highly profitable medical cannabis sales in Colombia, the United
Kingdom, Peru, Brazil, Germany and soon Mexico. The Company has been focused on
expanding its first-mover advantage where its health center's
physical installed capacity it's around 400,000 consults per year
in Colombia and more than 20,000
additional annual consults from the recent launch of Zerenia Clinic
in Brazil. By Q2 2022, Khiron had
exceeded the milestone of selling its first 100,000 bottles in the
Latin American region since beginning sales in 2020, maintaining
its high gross margins and pricing structure, with a strong
portfolio of THC and CBD medical cannabis products.
Khiron's CEO and Director, Alvaro
Torres, will be participating on a panel with industry
experts, entitled "International Momentum for Medical Cannabis"
taking place on Tuesday, September
13, at 2:55pm CT on the
Industry Stage, after announcing the acquisition of Pharmadrug
GmbH, an EU-GMP & GDP certified manufacturer and distributor in
Germany. Mr. Torres will also be
presenting Khiron's corporate presentation on Wednesday, September 14, at 11:50am CT on the Investor Stage.
About Khiron Life Sciences
Corp.
Khiron is a leading global medical cannabis company with core
operations in Latin America and
Europe. Leveraging wholly-owned
medical health clinics and proprietary telemedicine platforms,
Khiron combines a patient-oriented approach, physician education
programs, scientific expertise, product innovation, and focus on
creating access to drive prescriptions and brand loyalty with
patients worldwide. The Company has a sales presence in
Colombia, Germany, the United
Kingdom, Peru, and
Brazil and is positioned to
commence sales in Mexico. The
Company is led by its co-founder and Chief Executive Officer,
Alvaro Torres, together with an
experienced and diverse executive team and board of directors.
Visit Khiron online at https://investors.khiron.ca.
Linkedin
Cautionary Statement Regarding Forward-Looking
Information
This press release may contain "forward-looking information"
within the meaning of applicable securities legislation. All
information contained herein that is not historical in nature
constitutes forward-looking information. Forward-looking
information contained in this news release may include statements
pertaining to the expected synergies and benefits to the Company
from the acquisition of the Target as well as statements as to
business strategy. Forward-looking information and statements
contained in this news release reflect management's current beliefs
and is based on information currently available and on assumptions
that management believes to be reasonable. These assumptions
include, but are not limited to, the expected benefits to be
realized by Khiron's business as a result of the acquisition of the
Target, and assumptions regarding market opportunities in the
jurisdictions in which the Company operates and where it seeks to
operate.
Although management believes that its expectations and
assumptions to be reasonable, forward-looking information is always
subject to known and unknown risks, uncertainties and other
factors, many of which are beyond the control of management, that
may cause actual results to differ materially from those expressed
or implied in such forward-looking information. Such risks and
uncertainties include but are not limited to the following: general
economic conditions, adverse conditions in capital markets,
political uncertainties, counterparty risk, failing to obtain
required regulatory requirements and approvals, failure to maintain
required permits and licences, business integration risks, as well
as those other risk factors discussed in Khiron's most recent
annual information form which is available on Khiron's SEDAR
profile at www.sedar.com.
As a result of the foregoing and other risks and uncertainties,
readers are cautioned not to place undue reliance on
forward-looking information contained in this press release.
Readers are further cautioned that the foregoing risks and
uncertainties is not exhaustive, and there may be other risks and
uncertainties, presently unknown to management of the Company, that
may cause actual results to differ materially from those expressed
or implied in forward-looking statements contained in this press
release. The forward-looking information contained in this press
release is expressly qualified by this cautionary statement. Khiron
disclaims any intention to update or revise any forward-looking
information disclosed herein, whether as a result of new
information, future events or otherwise, except as required by
law.
NEITHER THE TSX VENTURE EXCHANGE, NOR ITS REGULATION SERVICES
PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX
VEMTIRE EXCHANGE), ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS PRESS RELEASE.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-life-sciences-awarded-best-latin-american-cannabis-company-at-benzinga-cannabis-capital-conference-301623370.html
SOURCE Khiron Life Sciences Corp.